stock logo

56% Buy

Laurus Labs Share Price

LAURUSLABS

₹440.40-₹16.60 (-3.63%) TodayLast updated on 19 Jul, 2024 | 15:47 IST
₹439.10₹458.40
L
Show Current Price
H
  • News

  • Company overview

  • Fundamentals

  • Events

  • F&O (Option chain)

  • More

Company overview

Financial performance

arrow

Market cap

Market Cap Switch₹24,640 Crs

Open

₹458.30

Close

₹457.00

Circuit range

₹484.40 - ₹396.40

Day range

₹439.10 - ₹458.40

Year range

₹328.15 - ₹484.30

Volume

23,98,591

Avg. traded

₹444.58

Revenue (12m)

₹5,041 Crs

Laurus Labs

Laurus Labs is an Indian pharmaceutical and biotechnology company. It is headquartered in Hyderabad and was founded in 2005.

Initially founded as a CRAMS (contract research and manufacturing services) enterprise, the company swiftly diversified into antiretroviral drugs (ARVs). Within five years, it transitioned into a respected active pharmaceutical ingredients (API) focused company. Another half-decade later, Laurus Labs expanded into a fully integrated pharmaceutical company.

The market capitalisation of Laurus Labs Limited is over ₹22,600 crore as of January 10, 2024. Laurus Labs share price has gained over 18% in the last three years.

Business operations

Laurus Labs specialises in the development, production and distribution of pharmaceutical ingredients and their related intermediates worldwide. It also offers a range of services to the global pharmaceutical industry, including drug discovery, medicinal chemistry, lead optimisation, process development, scale-up, safety assessment, formulation development and analytical chemistry services for its clientele.

Laurus Labs operates through three primary business segments. Firstly, Laurus Generics focuses on the development, manufacturing, and sale of APIs and advanced intermediates, along with oral solid formulations and finished dosage forms (FDFs). Secondly, Laurus Synthesis specialises in key starting materials (KSM), intermediates and APIs, particularly for new chemical entities (NCEs). Laurus Bio concentrates on recombinant products, producing animal-origin-free products for safer and virus-free bio-manufacturing processes.

Laurus Limited collaborates with the top 10 global generic pharmaceutical companies, distributing its APIs across 56 countries. The company concentrates primarily on developing anti-retroviral, Hepatitis C and oncology drugs.

Laurus Limited is also deeply involved in the research and development (R&D) in high-growth potential areas. With a total of 322 filed patents, it currently owns 203. Over its operational tenure, Laurus Limited has successfully brought more than 60 products to market, spread across three distinct business segments: Generics API, generics finished dosage form (FDF) and synthesis.

The company has over 55 state-of-the-art R&D labs strategically positioned in India and the US. It manufactures a staggering 90-plus APIs across ten cutting-edge manufacturing facilities which have over 7 million litres of reactor capacity. The company has a workforce comprising over 5,000 professionals, among which 800-plus are dedicated research scientists. This team serves more than 200 customers spread across 56 countries.

Laurus Labs has API manufacturing facilities in Visakhapatnam, an FDF drug manufacturing facility situated in Achutapuram and a research and development centre at IKP Knowledge Park in Hyderabad. The Hyderabad centre is also approved by the Department of Scientific and Industrial Research, Ministry of Science and Technology of India (DSIR).

With its manufacturing and R&D, Laurus is among the global leaders in supplying anti-retroviral APIs and intermediates. Its cost-effective technologies contribute to improving access to affordable medication worldwide. Oncology is Laurus Limited's key strength. It offers an extensive range of APIs in this domain. Laurus consistently expands its portfolio and its focus extends to molecules in diabetes, ophthalmology and cardiovascular therapy areas.

Financial highlights

Laurus Labs Limited's revenue from operations for FY23 stood at ₹6,040.55 crore, up by 22.4%, as compared to ₹4,935.57 crore in FY22. The net profit after tax for FY23 was ₹793.43 crore compared to ₹832.23 crore during the previous year. In FY23, the earnings before interest, tax, depreciation and amortisation (EBITDA) increased to ₹1,594 crore from the previous year's ₹1,436 crore. The company's earnings per share (EPS) stood at ₹14.69 in FY23 compared to ₹15.42 in FY22.

Laurus Labs Key indicators

arrow

52 week high

₹484.30

52 week low

₹328.15

P/E ratio

153.72

P/B ratio

6.02

ROE

5.44%

ROCE

7.54%

Dividend yield

0.18%

Debt/Equity ratio

0.49

EPS

4.15

Learn more

Investment checklist: (4/6)

arrow
check status

Equity returns

check status

Dividend returns

check status

Safety factor

check status

Growth factor

check status

Debt vs Equity

check status

Profit factor

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Analyst ratings:

Buy

arrow

Buy

56%

Hold

11%

Sell

33%

This analysis is based on the reviews of 9 experts in the last 7 days

Fundamentals

Financial ratios

arrow
  • Profitability

  • Operational

  • Valuation

Operating profit margin

16.57%

Net profit margin

4.65%

ROE

5.44%

ROA

2.77%

ROCE

7.54%

Learn more

Laurus Labs Shareholder returns

arrow

1 day

-3.63%

1 week

-6.61%

1 month

+2.34%

3 months

+3.26%

1 year

+25.54%

3 years

-33.73%

5 years

+526.55%

Laurus Labs Share Price history

arrow
DayOpenCloseDay’s change
Fri, Jul 19 2024
₹458.30
₹440.40
-3.63%
Thu, Jul 18 2024
₹464.00
₹457.00
-1.73%
Tue, Jul 16 2024
₹467.60
₹465.05
-0.25%
Mon, Jul 15 2024
₹464.50
₹466.20
+0.60%
Fri, Jul 12 2024
₹473.90
₹463.40
-1.73%
Thu, Jul 11 2024
₹474.00
₹471.55
-0.26%
Wed, Jul 10 2024
₹483.00
₹472.80
-1.48%
Tue, Jul 9 2024
₹475.55
₹479.90
+1.15%

Shareholding info

arrow

Promoters (27.18%)

Mutual Funds (9.18%)

Retail and other (33.59%)

Foreign institutions-FII (25.67%)

Other domestic institutions (4.38%)

Retail and other

Learn more

Events

Corporate actions

arrow
  • Dividend • ₹0.4/share

    Ex date 08 May 2024

    expand tab
  • Dividend • ₹0.4/share

    Ex date 02 Nov 2023

    expand tab
  • Dividend • ₹1.2/share

    Ex date 10 May 2023

    expand tab
  • Dividend • ₹0.8/share

    Ex date 03 Nov 2022

    expand tab
  • Dividend • ₹1.2/share

    Ex date 10 May 2022

    expand tab
  • Dividend • ₹0.8/share

    Ex date 17 Nov 2021

    expand tab

Learn more

Frequently asked questions